$15.21
1.49% today
Nasdaq, Oct 02, 05:50 pm CET
ISIN
US28036F1057
Symbol
EWTX

Edgewise Therapeutics Inc Stock price

$15.44
+1.09 7.60% 1M
-4.69 23.30% 6M
-11.26 42.17% YTD
-11.87 43.46% 1Y
+5.72 58.85% 3Y
-14.56 48.53% 5Y
-14.56 48.53% 10Y
-14.56 48.53% 20Y
Nasdaq, Closing price Wed, Oct 01 2025
-0.78 4.81%
ISIN
US28036F1057
Symbol
EWTX
Industry

Key metrics

Basic
Market capitalization
$1.6b
Enterprise Value
$1.0b
Net debt
positive
Cash
$594.0m
Shares outstanding
105.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
94.3%
Return on Equity
-29.1%
ROCE
-29.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-172.2m | $-190.4m
EBIT
$-174.5m | $-190.7m
Net Income
$-150.7m | $-173.4m
Free Cash Flow
$-125.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-28.3% | -21.6%
EBIT
-28.2% | -20.1%
Net Income
-30.0% | -29.6%
Free Cash Flow
-20.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.4
FCF per Share
$-1.2
Short interest
9.6%
Employees
126
Rev per Employee
$0.0
Show more

Is Edgewise Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Edgewise Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Edgewise Therapeutics Inc forecast:

15x Buy
83%
3x Hold
17%

Analyst Opinions

18 Analysts have issued a Edgewise Therapeutics Inc forecast:

Buy
83%
Hold
17%

Financial data from Edgewise Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 36 36
35% 35%
-
- Research and Development Expense 139 139
26% 26%
-
-172 -172
28% 28%
-
- Depreciation and Amortization 2.35 2.35
18% 18%
-
EBIT (Operating Income) EBIT -175 -175
28% 28%
-
Net Profit -151 -151
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Edgewise Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edgewise Therapeutics Inc Stock News

Neutral
PRNewsWire
about 4 hours ago
BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th International Annual Congress of the World Muscle Society (WMS).
Neutral
PRNewsWire
29 days ago
BOULDER, Colo. , Sept. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on August 29, 2025, Edgewise granted inducement stock options to purchase a total of 16,500 shares of Edgewise's com...
Neutral
GlobeNewsWire
about 2 months ago
Investors can contact the law firm at no cost to learn more about recovering their losses
More Edgewise Therapeutics Inc News

Company Profile

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Head office United States
CEO Kevin Koch
Employees 126
Founded 2017
Website edgewisetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today